Drug Trial Radar · NCT03682536
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
363
Actual
Start
Jan 2, 2019
Primary completion
Mar 31, 2023
Study completion Sep 28, 2027
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- First posted
- Sep 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in participants with anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require RBC transfusions and have never been exposed to erythropoiesis stimulating agent (ESA).
Conditions
- Myelodysplastic Syndromes
Interventions
LuspaterceptDrug
Specified dose on specified days
Epoetin alfaDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Red Blood Cell Transfusion Independence (RBC-TI) for 12 Weeks (84 Days) With a Mean Hemoglobin Increase ≥ 1.5 g/dLTime frame: Week 1 through Week 24
Locations
226 sites in 26 countries. Site status is shown where the registry gives one.
Local Institution - 107
Berkeley, California
Local Institution - 115
San Diego, California
Local Institution - 101
Whittier, California
Local Institution - 104
New Haven, Connecticut
Local Institution - 136
Washington D.C., District of Columbia
Local Institution - 119
Hudson, Florida
Local Institution - 120
St. Petersburg, Florida
Local Institution - 122
Tallahassee, Florida
Local Institution - 108
Tampa, Florida
Local Institution - 118
West Palm Beach, Florida
Local Institution - 102
Paducah, Kentucky
Local Institution - 123
Bethesda, Maryland
Local Institution - 117
Kansas City, Missouri
Local Institution - 134
East Brunswick, New Jersey
Local Institution - 113
Hackensack, New Jersey
Local Institution - 105
Greenville, North Carolina
Local Institution - 131
Portland, Oregon
Univ of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Local Institution - 111
Rock Hill, South Carolina
Tennessee Oncology
Nashville, Tennessee
Baylor University Medical Center
Dallas, Texas
Local Institution - 109
Houston, Texas
Local Institution - 114
Salt Lake City, Utah
Local Institution - 132
Charlottesville, Virginia
Local Institution - 127
Chesapeake, Virginia
Local Institution - 212
Randwick, Australia
Local Institution - 206
Albury, New South Wales, Australia
Local Institution - 213
Blacktown, New South Wales, Australia
Local Institution - 200
Concord, New South Wales, Australia
Local Institution - 215
Kogarah, New South Wales, Australia
Local Institution - 211
Nowra, New South Wales, Australia
Local Institution - 210
Waratah, New South Wales, Australia
Local Institution - 207
Wollongong, New South Wales, Australia
Local Institution - 208
Auchenflower, Queensland, Australia
Local Institution - 202
Adelaide, South Australia, Australia
Local Institution - 204
Clayton, Victoria, Australia
Local Institution - 203
Malvern, Victoria, Australia
Local Institution - 209
Melbourne, Victoria, Australia
Local Institution - 205
West Perth, Western Australia, Australia
Local Institution - 442
Linz, Austria
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.